Citations

Clear

92 citation(s) found for "Johnson, Sarah".

Cervical spondylotic myelopathy and driving abilities: defining the prevalence and long-term postoperative outcomes using the Quality Outcomes Database
Agarwal, Nitin , Johnson, Sarah E. , Bydon, Mohamad , Bisson, Erica F. , Chan, Andrew K. , Shabani, Saman , Michalopoulos, Giorgos D. , Lu, Daniel C. , Wang, Michael Y. , Haid, Regis W., Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Glassman, Steven D. , Shaffrey, Mark E., Foley, Kevin T. , Pennicooke, Brenton , Coric, Domagoj , Slotkin, Jonathan R., Upadhyaya, Cheerag D., Potts, Eric A. , Tumialán, Luis M. , Chou, Dean , Fu, Kai-Ming, Asher, Anthony L. , Mummaneni, Praveen V. , Michalopoulos, Giorgos , Letchuman, Vijay , Lavadi, Raj Swaroop , Goldberg, Jacob L. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | April 16, 2024 | Volume: 40 | Issue: 5 | Pages: 630-641

10.3171/2023.11.spine23738 | PMID 38364219 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) can cause significant difficulty with driving and a subsequent reduction in an individual’s quality of life due to neurological deterioration. The positive impact of surgery on postoperative patient-reported driving capabilities has been seldom explored. METHODS The CSM module of the Quality Outcomes Database was utilized. Patient-reported driving ability was assessed via the driving section of the Neck Disability Index (NDI) questionnaire. This is an ordinal scale in which 0 represents the absence of symptoms while driving and 5 represents a complete inability to drive due to symptoms. Patients were considered to have an impairment in their driving ability if they reported an NDI driving score of 3 or higher (signifying impairment in driving duration due to symptoms). Multivariable logistic regression models were fitted to evaluate mediators of baseline impairment and improvement at 24 months after surgery, which was defined as an NDI driving score < 3. RESULTS A total of 1128 patients who underwent surgical intervention for CSM were included, of whom 354 (31.4%) had baseline driving impairment due to CSM. Moderate (OR 2.3) and severe (OR 6.3) neck pain, severe arm pain (OR 1.6), mild-moderate (OR 2.1) and severe (OR 2.5) impairment in hand/arm dexterity, severe impairment in leg use/walking (OR 1.9), and severe impairment of urinary function (OR 1.8) were associated with impaired driving ability at baseline. Of the 291 patients with baseline impairment and available 24-month follow-up data, 209 (71.8%) reported postoperative improvement in their driving ability. This improvement seemed to be mediated particularly through the achievement of the minimal clinically important difference (MCID) in neck pain and improvement in leg function/walking. Patients with improved driving at 24 months noted higher postoperative satisfaction (88.5% vs 62.2%, p < 0.01) and were more likely to achieve a clinically significant improvement in their quality of life (50.7% vs 37.8%, p < 0.01). CONCLUSIONS Nearly one-third of patients with CSM report impaired driving ability at presentation. Seventy-two percent of these patients reported improvements in their driving ability within 24 months of surgery. Surgical management of CSM can significantly improve patients’ driving abilities at 24 months and hence patients’ quality of life.
The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study
Warnick, Ronald E. , Adam, Elizabeth , Iorio‐Morin, Christian , Leduc, William, Hamel, Andréanne, Johnson, Sarah E. , Bydon, Mohamad , Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Waite, Kaitlin, Jose, Shalini, Peker, Selçuk , Samanci, Mustafa Yavuz, Tek, Ece, Pikis, Stylianos , Sheehan, Jason P. , Kumar, Narendra , Bernstein, Kenneth , Ahorukomeye, Peter , Kshettry, Varun R. , Hernández, Wenceslao, Urgošík, Dušan, Lee, John Y. K., Patel, Samir , Kusyk, Dorian , Shepard, Matthew J., Samancı, Yavuz , Paddick, Ian , Mathieu, David , Mantziaris, Georgios , Tripathi, Manjul , Alzate, Juan Diego , Speckter, Herwin , Liščák, Roman , Yang, Andrew I. , Kondziolka, Douglas

Mayo Clinic

Journal of Neurosurgery | February 17, 2024 | Volume: 141 | Issue: 2 | Pages: 461-473

10.3171/2023.12.jns231569 | PMID 38364220 Get It

OBJECTIVE Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
Transforming Outcomes of Spine Surgery—Exploring the Power of Enhanced Recovery After Surgery Protocol: A Systematic Review and Meta-Analyses of 15 198 Patients
Magableh, Hamzah M , Ibrahim, Sufyan , Pennington, Zach , Nathani, Karim Rizwan , Johnson, Sarah E. , Freedman, Brett A. , Bydon, Mohamad , Pennington, Zachary, Katsos, Konstantinos, Pennington, Zach , Nathani, Karim Rizwan , Ibrahim, Sufyan , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | February 15, 2024 | Volume: 95 | Issue: 1 | Pages: 3-25

10.1227/neu.0000000000002865 | PMID 38358272 Get It

BACKGROUND AND OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols aim to optimize patient outcomes by reducing the surgical stress response, expediting recovery, and reducing care costs. We aimed to evaluate the impact of implementing ERAS protocols on the perioperative surgical outcomes and financial implications associated with spine surgeries. METHODS: A systematic review and meta-analysis of peer-reviewed studies directly comparing outcome differences between spine surgeries performed with and without utilization of ERAS pathways was conducted along Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Of 676 unique articles identified, 59 with 15 198 aggregate patients (7748 ERAS; 7450 non-ERAS) were included. ERAS-treated patients had shorter operative times (mean difference [MD]: 10.2 mins; P < .01), shorter hospitalizations (MD: 1.41 days, P < .01), fewer perioperative complications (relative risk [RR] = 0.64, P < .01), lower postoperative opioid use (MD of morphine equivalent dose: 164.36 mg; P < .01), and more rapid mobilization/time to first out-of-bed ambulation (MD: 0.92 days; P < .01). Spine surgeries employing ERAS were also associated with lower total costs (MD: $1140.26/patient; P < .01), especially in the United States (MD: $2869.11/patient, P < .01) and lower postoperative visual analog pain scores (MD = 0.56, P < .01), without any change in odds of 30-day readmission (RR: 0.80, P = .13) or reoperation (RR: 0.88, P = .60). Subanalyses based on the region of spine showed significantly lower length of stay in both cervical and lumbar surgeries implementing ERAS. Type of procedure showed a significantly lesser time-to-initiate mobilization in fusion surgeries using ERAS protocols compared with decompression. CONCLUSION: The present meta-analysis indicates that current literature supports ERAS implementation as a means of reducing care costs and safely accelerating hospital discharge for patients undergoing spine surgery.
Commentary: A Quantitative Assessment of Chat-GPT as a Neurosurgical Triaging Tool
Bydon, Mohamad , Johnson, Sarah E. , Katsos, Konstantinos, Johnson, Sarah E , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | February 14, 2024 | Volume: 95 | Issue: 2 | Pages: e44-e44

10.1227/neu.0000000000002880 | PMID 38353559 Get It

Complex balanced intrachromosomal rearrangement involving PITX2 identified as a cause of Axenfeld‐Rieger Syndrome
Farris, Joseph , Khanna, Cheryl L. , Smadbeck, James B. , Johnson, Sarah H. , Bothun, Erick D. , Kaplan, Tyler, Hoffman, Francis, Polonis, Katarzyna , Reis, Linda M. , Rust, Laura, Hoppman, Nicole L., Vasmatzis, George , Marcou, Cherisse A. , Schimmenti, Lisa A. , Klee, Eric W. , Khanna, Cheryl, Bothun, Erick, Oliver, Gavin, Schimmenti, Lisa A , Farris, Joseph D , Hoffman, Francis, Oliver, Gavin R. , Semina, Elena V.

Mayo Clinic

American Journal of Medical Genetics Part A | January 18, 2024 | Volume: 194 | Issue: 5 | Pages: No page available

10.1002/ajmg.a.63542 | PMID 38234180 Get It

AbstractAxenfeld‐Rieger Syndrome (ARS) type 1 is a rare autosomal dominant condition characterized by anterior chamber anomalies, umbilical defects, dental hypoplasia, and craniofacial anomalies, with Meckel's diverticulum in some individuals. Here, we describe a clinically ascertained female of childbearing age with ARS for whom clinical targeted sequencing and deletion/duplication analysis followed by clinical exome and genome sequencing resulted in no pathogenic variants or variants of unknown significance in PITX2 or FOXC1. Advanced bioinformatic analysis of the genome data identified a complex, balanced rearrangement disrupting PITX2. This case is the first reported intrachromosomal rearrangement leading to ARS, illustrating that for patients with compelling clinical phenotypes but negative genomic testing, additional bioinformatic analysis are essential to identify subtle genomic abnormalities in target genes.
EXTH-37. FUNCTIONAL GENOMICS IDENTIFIES THERAPEUTIC VULNERABILITIES OF GLIOMA SUBTYPES AND YAP/TAZ-ENRICHED TUMORS
Lin, Wan‐Hsin , Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan W. , Penheiter, Alan R. , Lynch, Jamie, Sadeghian, Dorsay, Maruthi, Vijaya Kadam, Johnson, Sarah H. , Karagouga, Giannoula, Harris, Faye R. , Berry, T. Dennis, McCune, Alexa, Kinsella, Lindsey, Yang, Lin , Emanuel, Angela, Salvatori, Rebecca , Klein, Janet Schaefer, Ida, Cristine, Jentoft, Mark E. , Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven S. , Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugała, Maciej M. , Quiñones‐Hinojosa, Alfredo , Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Kizilbash, Sani H , Sotiriou, Sotiris , Berry, Taylor, Murphy, Stephen J. , Moniz‐Garcia, Diogo , Ensign, Shannon P. Fortin , Salomao, Marcela , Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v232-v232

10.1093/neuonc/noad179.0890 Get It

Abstract Sequencing efforts have identified key oncogenic drivers and transcriptomic subtypes of high-grade gliomas (HGGs), but this knowledge has not resulted in individualized therapy or improved patient outcomes. Here, we used a functional genomics approach combining integrated genomic/transcriptomic analyses with patient-derived 3D micro-cancers (mCancers) to rapidly identify individualized therapeutic vulnerabilities and determine predictive response biomarkers. 30 primary/recurrent HGGs, including 20 glioblastomas, 5 astrocytomas, and 5 oligodendrogliomas, were included for drug testing. mCancers recapitulated the structural and molecular alterations, cellularity, and heterogeneity, of parental patient tumors. A total of 119 single-agent drugs and 183 drug combinations were tested, while a pre-selected drug panel comprising 25 glioma-relevant treatment strategies was tested across all cases. In general, mCancer efficacy corresponded well to historical responses to previously tested agents (EGFR, HDAC inhibitors, etc.). Combined, strong efficacy (i.e. &gt;70% growth inhibition at Cmax) of single treatments targeting deregulated receptor tyrosine kinase (RTK), p53/apoptosis, cell cycle, DNA damage repair, IDH, or telomere maintainance pathways, was observed in 14 out of 30 cases. Surprisingly, transcriptional signatures, but not specific genetic alterations, were found to stratify drug responses. For example, mCancers enriched for the most aggressive mesenchymal (MES) and glycolytic/plurimetabolic (GPM) transcriptional subtypes exhibited stronger response to the BET inhibitor JQ1 (and other clinical BET inhibitors) and the DNA-PKcs/mTOR dual inhibitor CC-115. This therapeutic vulnerability was associated with enrichment of YAP/TAZ signaling, and the glioblastoma stem cell G-STEM signature. Notably, individual combination strategies were effective across tumors, with strong responses ranging from 38% to 77% of all tumors tested. Overall, this study underscores the value of functional genomics in identifying novel vulnerabilities of HGGs and associated response biomarkers. It also highlights the need for further clinical validation of several novel therapies and especially drug combination strategies with strong efficacy in the ex vivo setting.
Surgical management of malignant melanotic nerve sheath tumors: an institutional experience and systematic review of the literature
Johnson, Sarah E. , Ghanem, Marc , Michaelides, Loizos , Nieves, Antonio Bon, Marsh, W. Richard , Currier, Bradford L. , Atkinson, John L. D., Spinner, Robert J. , Bydon, Mohamad , Bon‐Nieves, Antonio , El-Hajj, Victor Gabriel , Bon Nieves, Antonio, Bon-Nieves, Antonio A , Ghaith, Abdul Karim , Akinduro, Oluwaseun O. , Biase, Gaetano De

Mayo Clinic

Journal of Neurosurgery: Spine | October 21, 2023 | Volume: 40 | Issue: 1 | Pages: 28-37

10.3171/2023.8.spine23427 | PMID 37862711 Get It

OBJECTIVE Malignant melanotic nerve sheath tumors are rare tumors characterized by neoplastic melanin-producing Schwann cells. In this study, the authors report their institution’s experience in treating spinal and peripheral malignant melanotic nerve sheath tumors and compare their results with the literature. METHODS Data were collected from 8 patients who underwent surgical treatment for malignant melanotic nerve sheath tumors between 1996 and 2023 at Mayo Clinic and 63 patients from the literature. Time-to-event analyses were performed for the combined group of 71 cases to evaluate the risk of recurrence, metastasis, and death based on tumor location and type of treatment received. Unpaired 2-sample t-tests and Fisher’s exact tests were used to determine statistical significance between groups. RESULTS Between 1996 and 2023, 8 patients with malignant melanotic nerve sheath tumors underwent surgery at the authors’ institution, while 63 patients were identified in the literature. The authors’ patients and those in the literature had the same mean age at diagnosis (43 years). At the authors’ institution, 5 patients (63%) experienced metastasis, 6 patients (75%) experienced long-term recurrence, and 5 patients (62.5%) died. In the literature, most patients (60.3%) were males, with a peak incidence between the 4th and 5th decades of life. Nineteen patients (31.1%) were diagnosed with Carney complex. Nerve root tumors accounted for most presentations (n = 39, 61.9%). Moreover, 24 patients (38.1%) had intradural lesions, with 54.2% (n = 13) being intramedullary and 45.8% (n = 11) extramedullary. Most patients underwent gross-total resection (GTR) (n = 41, 66.1%), followed by subtotal resection (STR) (n = 12, 19.4%), STR with radiation therapy (9.7%), and GTR with radiation therapy (4.8%). Sixteen patients (27.6%) experienced metastasis, 23 (39.7%) experienced recurrence, and 13 (22%) died. Kaplan-Meier analyses showed no significant differences among treatment approaches in terms of recurrence-free, metastasis-free, and overall survival (p > 0.05). Similar results were obtained when looking at the differences with respect to intradural versus nerve root location of the tumor (p > 0.05). CONCLUSIONS Malignant melanotic nerve sheath tumors are rare tumors with a high potential for malignancy. They carry a dismal prognosis, with a pooled local recurrence rate of 42%, distant metastasis rate of 27%, and mortality rate of 26%. The findings from this study suggest a trend favoring the use of GTR alone or STR with radiation therapy over STR alone. Mortality was similar regardless, which highlights the need for the development of effective treatment options to improve survival in patients with melanotic schwannomas.
Intraoperative Surgeon Assessment of Bone
Bernatz, James T. , Skjaerlund, Jonathan, Mikula, Anthony L. , Johnson, Sarah E. , Bydon, Mohamad , Fogelson, Jeremy L. , Elder, Benjamin D. , Sebastian, Arjun S. , Freedman, Brett A. , Goh, Brian C, Skjaerlund, Jonathan D, Fogelson, Jeremy, Elder, Benjamin, Huddleston, Paul, Karim, Mohammed, Sebastian, Arjun, Goh, Brian Chun Kim , Huddleston, P.M. , Karim, Mohammed, Nassr, Ahmad

Mayo Clinic

Spine | October 19, 2023 | Volume: 49 | Issue: 16 | Pages: 1125-1129

10.1097/brs.0000000000004854 | PMID 37855301 Get It

Study design. Retrospective observational study of consecutive patients. Objective. The purpose of the study is to determine if a surgeon’s qualitative assessment of bone intraoperatively correlates with radiologic parameters of bone strength. Summary of Background Data. Preoperative radiologic assessment of bone can include modalities such as computed tomography (CT) Hounsfield units (HUs), dual-energy x-ray absorptiometry (DXA) bone mineral density with trabecular bone score (TBS) and magnetic resonance imaging vertebral bone quality (VBQ). Quantitative analysis of bone with screw insertional torque and pull-out strength measurement has been performed in cadaveric models and has been correlated to these radiologic parameters. However, these quantitative measurements are not routinely available for use in surgery. Surgeons anecdotally judge bone strength, but the fidelity of the intraoperative judgment has not been investigated. Methods. All adult patients undergoing instrumented posterior thoracolumbar spine fusion by one of seven surgeons at a single center over a 3-month period were included. Surgeons evaluated the strength of bone based on intraoperative feedback and graded each patient’s bone on a 5-point Likert scale. Two independent reviewers measured preoperative CT HUs and magnetic resonance imaging VBQ. Bone mineral density, lowest T-score, and TBS were extracted from DXA within 2 years of surgery. Results. Eighty-nine patients were enrolled and 16, 28, 31, 13, and 1 patients had Likert grade 1 (strongest bone), 2, 3, 4, and 5 (weakest bone), respectively. The surgeon assessment of bone correlated with VBQ (τ=0.15, P=0.07), CT HU (τ=−0.31, P<0.01), lowest DXA T-score (τ=−0.47, P<0.01), and TBS (τ=−0.23, P=0.06). Conclusion. Spine surgeons’ qualitative intraoperative assessment of bone correlates with preoperative radiologic parameters, particularly in posterior thoracolumbar surgeries. This information is valuable to surgeons as this supports the idea that decisions based on feel in surgery have a statistical foundation.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Engstrom, Lars D. , Aranda, Ruth , Waters, Laura , Moya, Krystal , Bowcut, Vickie , Vegar, Laura , Trinh, David , Hebbert, Allan , Smith, Christopher R. , Kulyk, Svitlana , Lawson, J. David , He, Leo , Hover, Laura D. , Hallin, Jill , Vanderpool, Darin , Briere, David M. , Blaj, Alice , Arbour, Kathryn C. , Jänne, Pasi A. , Papadopoulos, Kyriakos P. , Henry, Jason T. , Leventakos, Konstantinos , Christensen, James G. , Shazer, Ronald , Olson, Peter , Fernandez-Banet, Julio , Hallin, Jill , Vanderpool, Darin , Briere, David M , Blaj, Alice , Marx, Matthew A , Rodon, Jordi , Offin, Michael , Arbour, Kathryn C , Johnson, Melissa L , Kwiatkowski, David J. , Jänne, Pasi A , Haddox, Candace L , Papadopoulos, Kyriakos P , Henry, Jason T , Leventakos, Konstantinos , Christensen, James G , Shazer, Ronald , Olson, Peter , Johnson, Melissa L. , Haddox, Candace L.

Mayo Clinic

Cancer Discovery | August 8, 2023 | Volume: 13 | Issue: 11 | Pages: 2412-2431

10.1158/2159-8290.cd-23-0669 | PMID 37552839 Get It

Abstract Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with &gt;70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293
Abstract 3391: Dual inhibition of RAS and the IGF2/IGF1R pathways: a potential targeting strategy for RAS-mutated embryonal rhabdomyosarcoma
Sadeghian, Dorsay , Lin, Wan‐Hsin , Smadbeck, James B. , Panheiter, Alan, Barrett, Michael T. , McCune, Alexa, Karagouga, Giannoula, Johnson, Sarah H. , Feathers, Ryan W. , Harris, Faye R. , Kinsella, Lindsey, Berry, T. Dennis, Cheville, John C. , Anastasiadis, Panos Z. , Granberg, Candace F. , Gargollo, Patricio C. , Vasmatzis, George , Berry, Taylor

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 3391-3391

10.1158/1538-7445.am2023-3391 Get It

Abstract Background: Mutations in RAS is reported in embryonal rhabdomyosarcoma (ERMS). Upregulation of IGF2/IGF1R axis and IGF2 overexpression is a common finding. Targeting RAS downstream is associated with high toxicity. Combination therapies targeting parallel pathways is necessary to overcome treatment resistance. Dual inhibition of RAS downstream and IGF2/IGF1R axis can be a potential mechanism of targeted treatment. The efficacy of this mechanism was studied using a microcancer 3D exvivo tumor cell viability assay in a KRAS mutant ERMS. Design: Tumor was collected for a high-risk pediatric ERMS patient. Comprehensive genomic analysis, for identification of targetable genomic alterations, was performed by integrating WES, MPseq and RNAseq. Tumor spheroids grown in 3D environment were tested against multiple single drugs and combinations. The tumor viability was assed employing the Cell Titer Glow Luminescent Cell Viability Assay. Results were expressed as nMATP and were shown as drug-response curve exhibiting the ATP concentration changes at Cmax. Results: Genomic findings included an oncogenic KRAS (G12D) mutation. BAY-293 has a partial cell killing response as a single agent. Given to the presence of IGF2 over-expression, IGF2/IGF1R pathway was targeted by linsitinib. Addition of BAY-293 to linsitinib led to enhanced effectiveness of this agent (Table 1). Conclusion: Combination of comprehensive genomic profiling and a laboratory-based 3D micro-cancer model using the patient’s own tumor is an effective way to determine drug efficacy. Targeting RAS pathway by single agents, increases the possibility of resistance. Dual targeting of downstream pathways by MEK and PI3K pathway inhibition is highly toxic, and the clinical usage of this combination is limited. Our results have indicated inhibition of IGF-1R/IGF2 axis in combination with other agents targeting RAS pathway, can be a potential method to address these limitations. ABEL 1. Summary of molecular alterations and targeting methods Molecular alteration Drug Target Kill% at Cmax KRAS (G12D) Mutation BAY-293 RAS-SOS1 interaction 55.3 Trametinib MEK1/2 88.3 Selumetinib MEK1/2 76 Paxalisib PI3K/mTOR 89.7 Samotolisib PI3K/mTOR 92.9 Copanlisib PI3K 95.2 Perifosine AKT 89.2 IGF2 Over-expression Linsitinib IGF-1R/InsR 84.1 BMS-754807 IGF-1R/InsR 67.4 NTRK2 mutation Larotrectinib NTRK 41.9 KMT2D mutation Panobinostat HDAC 85.3 Combinations Kill% at Cmax BAY-293+Selumetinib 100 BAY-293+Samotolisib 100 BAY-293+Paxalisib 99.7 BAY-293+Linsitinib 97.5 Selumetinib+Samotolisib 93.1 Citation Format: Dorsay Sadeghian, Wan-Hsin Lin, James Smadbeck, Alan Panheiter, Michael Barrett, Alexa F. Mccune, Giannoula Karagouga, Sarah Johnson, Ryan W. Feathers, Faye R. Harris, Lindsey Kinsella, Taylor Berry, John Cheville, Panos Anastasiadis, Candace Granberg, Patricio Gargollo, Vasmatzis George. Dual inhibition of RAS and the IGF2/IGF1R pathways: a potential targeting strategy for RAS-mutated embryonal rhabdomyosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3391.